CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals (China) Co., Ltd, a company of limited • Beijing Zhongbai Biotechnology Co., Ltd. • Miikana Therapeutics, Inc. • CASI Biopharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (Hainan) Co., Ltd., a company of limited ...

IRS number

581959440

CASI stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

20-F

2022 FY

Annual report (foreign)

26 Apr 23

EFFECT

Notice of effectiveness

27 Mar 23

15-12G

Securities registration termination

22 Mar 23

S-8 POS

Registration of securities for employees (post-effective amendment)

21 Mar 23

S-8 POS

Registration of securities for employees (post-effective amendment)

21 Mar 23

S-8 POS

Registration of securities for employees (post-effective amendment)

21 Mar 23

S-8 POS

Registration of securities for employees (post-effective amendment)

21 Mar 23

POS AM

Prospectus update (post-effective amendment)

21 Mar 23

8-K

Submission of Matters to a Vote of Security Holders

21 Mar 23

DEF 14A

Definitive proxy

14 Feb 23

Transcripts

View all

CASI

Earnings call transcript

2022 Q2

12 Aug 22

CASI

Earnings call transcript

2022 Q1

12 May 22

CASI

Earnings call transcript

2021 Q4

28 Mar 22

CASI

Earnings call transcript

2021 Q3

13 Nov 21

CASI

Earnings call transcript

2021 Q2

13 Aug 21

CASI

Earnings call transcript

2021 Q1

19 May 21

CASI

Earnings call transcript

2020 Q3

10 Nov 20

CASI

Earnings call transcript

2020 Q2

10 Aug 20

Latest ownership filings

View all

FEDERATED HERMES, INC.

9 Feb 23

SC 13G/A

FEDERATED HERMES, INC.

Financial summary

Financial statements Chart CASI financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	47.11 mm	47.11 mm	47.11 mm	47.11 mm	47.11 mm	47.11 mm
Cash burn (monthly)	(no burn)	(no burn)	4.21 mm	2.93 mm	281.00 k	1.76 mm
Cash used (since last report)	n/a	n/a	105.35 mm	73.21 mm	7.02 mm	43.93 mm
Cash remaining	n/a	n/a	-58.23 mm	-26.10 mm	40.09 mm	3.18 mm
Runway (months of cash)	n/a	n/a	-13.8	-8.9	142.7	1.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

CASI institutional ownership history Ownership history

27.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	12	21	-42.9%
Opened positions	2	9	-77.8%
Closed positions	11	3	+266.7%
Increased positions	2	4	-50.0%
Reduced positions	2	2	–

13F shares	Current	Prev Q	Change
Total value	1.08 bn	788.42 mm	+36.5%
Total shares	3.62 mm	3.93 mm	-7.9%
Total puts	0.00	0.00
Total calls	0.00	100.00	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Foresite Capital Fund VI	1.31 mm	$0.00	NEW
He Wei-Wu	1.10 mm	$0.00	0.0%
Huang James	1.02 mm	$0.00	-60.6%
Wellington Shields Capital Management	89.22 k	$490.69 mm	-3.3%
Wellington Shields & Co.	43.09 k	$237.00 mm	0.0%
Renaissance Technologies	40.80 k	$224.40 mm	+10.9%
Geode Capital Management	22.22 k	$122.22 mm	0.0%
Simplex Trading	1.04 k	$5.00 k	+67.3%
TD Waterhouse Canada	300.00	$1.31 mm	0.0%
West Paces Advisors	100.00	$550.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
Huang James	1.02 mm	-1.57 mm	-60.6%
Foresite Capital Fund VI	1.31 mm	+1.31 mm	NEW
Howland Capital Management	0.00	-40.43 k	EXIT
WFC Wells Fargo & Company	0.00	-12.01 k	EXIT
Renaissance Technologies	40.80 k	+4.00 k	+10.9%
Wellington Shields Capital Management	89.22 k	-3.00 k	-3.3%
MS Morgan Stanley	0.00	-1.44 k	EXIT
FMR	0.00	-500.00	EXIT
Simplex Trading	1.04 k	+419.00	+67.3%
BLK BlackRock	0.00	-296.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Earnings Scheduled For November 14, 2024

14 Nov 24

Press releases

From Benzinga Pro

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

6 Jan 25

BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

15 Nov 24

BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development